Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 23Terminated 9Active not recruiting 6Unknown 3Recruiting 3Withdrawn 1Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1

Interventions

Specimen Handling 29Magnetic Resonance Spectroscopy 18Biopsy 16Cyclophosphamide 15Nivolumab 10Paclitaxel 9Vincristine 8Cisplatin 8venetoclax 7Prednisone 7Gemcitabine 7Doxorubicin 7Bevacizumab 7Azacitidine 7pembrolizumab 6Radiotherapy 6Fluorouracil 6Etoposide 6Drug Therapy 6Docetaxel 6Rituximab 5Radiosurgery 5Oxaliplatin 5Irinotecan 5Injections 5Everolimus 5Capecitabine 5fludarabine phosphate 4Taxes 4Surgical Procedures, Operative 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Interventional × talimogene laherparepvec × Clear all
NCT04427306 2023-09-15

Neoadjuvant T-VEC in High Risk Early Melanoma

University of California, Davis

Phase 2 Suspended
6 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡